Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-4316 SCHEMBL2875158 | 0.88 | BCHE (0.37) | BCHE | |
| Azd-4316 SCHEMBL2878293 | 0.87 | BCHE (0.37) | BCHE | |
| Azd-4316 SCHEMBL2872620 | 0.87 | BCHE (0.37) | BCHE | |
| SCHEMBL2873272 | 0.85 | CNR2 (0.38) | CNR2 | |
| Azd-4316 SCHEMBL2869984 | 0.85 | BCHE (0.40) | CNR2BCHECNR1 | |
| Azd-4316 SCHEMBL2870503 | 0.82 | BCHE (0.38) | CNR2BCHECNR1 | |
| SCHEMBL2868989 | 0.81 | CNR2 (0.35) | CNR2 | |
| Azd-4316 SCHEMBL2870238 | 0.80 | HDAC1 (0.39) | CNR2BCHECNR1 | |
| Azd-4316 SCHEMBL2870235 | 0.80 | HDAC1 (0.39) | CNR2BCHECNR1 | |
| Azd-4316 SCHEMBL2873056 | 0.79 | BCHE (0.39) | CNR2BCHECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | claimed |
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | claimed |
| EP-3177299-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | Alios Biopharma, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2016022464-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | CNR2 2323/4885BCHE 3288/4885CNR1 995/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | CNR2 4519/4885BCHE 3404/4885CNR1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.